Astrazeneca PLC (AZN) Receives Average Rating of “Hold” from Brokerages
Astrazeneca PLC (NYSE:AZN) has been given an average rating of “Hold” by the thirty brokerages that are covering the stock, MarketBeat reports. Four analysts have rated the stock with a sell rating, ten have given a hold rating and fifteen have assigned a buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $34.54.
AZN has been the topic of several research analyst reports. Sanford C. Bernstein reissued a “buy” rating on shares of Astrazeneca PLC in a research note on Friday, September 22nd. Investec upgraded shares of Astrazeneca PLC from a “hold” rating to a “buy” rating in a report on Wednesday, August 9th. Leerink Swann downgraded shares of Astrazeneca PLC from an “outperform” rating to a “market perform” rating and lowered their price objective for the stock from $36.00 to $31.00 in a report on Thursday, July 27th. Argus restated a “buy” rating and set a $35.00 price objective on shares of Astrazeneca PLC in a report on Friday, September 1st. Finally, Goldman Sachs Group, Inc. (The) reiterated a “sell” rating on shares of Astrazeneca PLC in a report on Thursday, July 13th.
A number of large investors have recently modified their holdings of AZN. Meeder Asset Management Inc. bought a new position in Astrazeneca PLC during the second quarter worth about $105,000. WFG Advisors LP boosted its position in Astrazeneca PLC by 36.0% during the second quarter. WFG Advisors LP now owns 3,716 shares of the company’s stock worth $127,000 after purchasing an additional 984 shares during the period. Bronfman E.L. Rothschild L.P. boosted its position in shares of Astrazeneca PLC by 71.2% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 4,252 shares of the company’s stock valued at $145,000 after acquiring an additional 1,769 shares during the period. Quadrant Capital Group LLC boosted its position in shares of Astrazeneca PLC by 18.4% in the second quarter. Quadrant Capital Group LLC now owns 5,437 shares of the company’s stock valued at $147,000 after acquiring an additional 846 shares during the period. Finally, Westport Asset Management Inc. bought a new position in shares of Astrazeneca PLC in the second quarter valued at approximately $170,000. Hedge funds and other institutional investors own 14.17% of the company’s stock.
Astrazeneca PLC (NYSE AZN) traded down $0.20 during trading hours on Friday, hitting $32.91. 4,922,389 shares of the stock were exchanged, compared to its average volume of 4,860,991. The company has a debt-to-equity ratio of 1.09, a quick ratio of 0.73 and a current ratio of 0.91. Astrazeneca PLC has a 12 month low of $25.55 and a 12 month high of $35.60. The company has a market cap of $81,530.00, a price-to-earnings ratio of 7.59, a P/E/G ratio of 2.78 and a beta of 0.79.
Astrazeneca PLC (NYSE:AZN) last issued its earnings results on Thursday, November 9th. The company reported $1.12 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.57 by $0.55. The business had revenue of $6.23 billion for the quarter, compared to analyst estimates of $6 billion. Astrazeneca PLC had a net margin of 17.80% and a return on equity of 35.90%. Astrazeneca PLC’s revenue was up 9.4% on a year-over-year basis. During the same period in the prior year, the firm earned $1.32 earnings per share. equities analysts expect that Astrazeneca PLC will post 1.93 EPS for the current year.
Astrazeneca PLC Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Stock Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related stocks with our FREE daily email newsletter.